New Delhi, May 22 -- Pune-headquartered Emcure Pharmaceuticals plans to expand its gynaecology and dermatology product portfolio for the Indian market in FY26, the company's top executive said on Thursday.

"In women's health, we launched a portfolio of products in the menopause and PCOS segment [in FY25]," the company's CEO and managing director Satish Mehta told investors in a post-earnings call. "We are also in the process of deepening our presence in the gynaecology segment with further launches in FY26," he added.

The firm, which was listed on the stock exchanges in July 2024, reported a profit after tax of Rs.197 crore in Q4FY25, up 63% year-on-year. Revenue rose 19.5% YoY to Rs.2,116 crore.

The revenue growth was driven by 24.8% ...